Jideytro (zidesamtinib) for previously treated ros1-positive non-small cell lung cancer: a new era in post-tki therapy. (PubMed, Ann Med Surg (Lond)) - Oct 14, 2026 - "In the pivotal ARROS-1 trial, it produced durable responses in heavily pretreated patients, including those with brain metastases, with low treatment discontinuation. Although prospective comparisons with crizotinib, entrectinib, repotrectinib, and taletrectinib are needed, zidesamtinib represents an important addition to post-TKI therapy for ROS1-positive NSCLC."
Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ROS1
|
|
Md Tahmid Islam; Syeda Fadak Zahra Hujjat
|